S-891-119
Read twice and referred to the Committee on Finance.
Sponsored by Ron Wyden (D-OR)
What it does
This bill would extend and modify a wide range of expiring federal health programs across Medicaid, Medicare, and public health. It would streamline Medicaid provider enrollment across state lines, expand home and community-based care options, extend telehealth flexibilities, add Medicare coverage for multi-cancer screening tests and new drug categories, reform pharmacy benefit manager (PBM) practices, reauthorize opioid crisis response programs under the SUPPORT Act, reauthorize pandemic preparedness infrastructure, and extend funding for community health centers, diabetes programs, and the World Trade Center Health Program.
Who benefits
Medicare and Medicaid enrollees (approximately 160 million combined) who would gain access to extended telehealth, new cancer screenings, and expanded drug coverage. Adults with disabilities over age 65 who would gain Medicaid buy-in eligibility previously cut off by age limits. Military families relocated by active duty orders who would retain Medicaid and home-care waiting list status. Rural hospitals serving high proportions of Medicaid patients that would receive payment adjustments and maternity cost study support. Low-income Medicare Part D enrollees who would see adjusted cost-sharing. Independent pharmacies that would benefit from PBM transparency and spread-pricing restrictions. Patients with opioid use disorder and their families who would benefit from SUPPORT Act reauthorization. 9/11 responders and survivors covered by the World Trade Center Health Program. Children with rare diseases who would benefit from pediatric drug research extensions. Community health centers and National Health Service Corps sites serving underserved populations.
Who is hurt
Pharmacy benefit managers (PBMs) whose spread-pricing and rebate practices would face new restrictions and transparency requirements. Insurers and managed care organizations that may face higher administrative costs from new reporting and data-sharing mandates. States that would bear new administrative burdens from required address verification, deceased-enrollee screening, and maternity cost studies. Providers who currently benefit from inconsistent cross-state enrollment standards, which would be standardized. Pharmaceutical manufacturers of orphan drugs who would face new limitations on exclusive approval. Taxpayers who would bear the cost of new appropriations across multiple titles, including $71 million for home-care demonstration grants, $10 million for rural maternity hospital data assistance, and additional sums across pandemic preparedness and public health titles.
Supporters argue
Supporters argue that this bill addresses a well-documented patchwork of expiring provisions that, if allowed to lapse, would disrupt care for tens of millions of Americans who rely on Medicare and Medicaid. They contend that specific provisions — such as removing the age-65 cap on Medicaid disability buy-in, extending telehealth flexibilities used by over 28 million Medicare beneficiaries during and after the COVID-19 pandemic, and adding Medicare coverage for multi-cancer early detection tests — close concrete gaps in coverage that have measurable health consequences. They further argue that PBM spread-pricing restrictions and rebate pass-through requirements would reduce drug costs for patients and taxpayers by eliminating documented middleman markups that inflate Medicaid and Medicare drug spending.
Opponents argue
Opponents argue that the bill's breadth — spanning ten titles and hundreds of provisions — obscures its true fiscal cost and prevents meaningful congressional scrutiny of individual policy choices, a concern amplified by the post-Loper Bright environment in which agency implementation rules will face heightened judicial review. They contend that several provisions, such as the home and community-based services demonstration program and expanded Medicaid eligibility for older adults with disabilities, create open-ended federal spending commitments without sufficient cost controls, and that mandating new state administrative requirements — quarterly deceased-enrollee checks, address verification, and maternity cost studies — imposes unfunded burdens on state Medicaid agencies already strained by post-pandemic redetermination workloads.
Constitutional context
Congress exercises authority over Medicare and Medicaid under the Taxing and Spending Clause (Art. I, §8, cl. 1) and the Commerce Clause (Art. I, §8, cl. 3). New state administrative mandates tied to federal Medicaid funding must remain within the Spending Clause coercion limits identified in NFIB v. Sebelius (2012), which held that conditions cannot be so onerous as to leave states no genuine choice. Post-Loper Bright (2024), the numerous provisions delegating rulemaking authority to HHS and CMS will face independent judicial scrutiny rather than automatic deference, meaning ambiguous statutory language could be more readily challenged.
Checks and balances
The executive branch (HHS, CMS, FDA) gains significant new rulemaking and grant-distribution authority across all ten titles; congressional oversight is maintained through required reports, data submissions, and the existing appropriations process, while courts retain authority to review agency rules under the heightened post-Loper Bright standard.
Historical precedent
Omnibus health extender packages are a recurring legislative vehicle; the most directly analogous recent example is the Consolidated Appropriations Act of 2023, which similarly bundled Medicare and Medicaid extenders, telehealth flexibilities, and public health reauthorizations into a single omnibus measure.